Patterns of viral load in chronic hepatitis B patients in Brazil and their association with ALT levels and HBeAg status |
| |
Affiliation: | 2. Diagnósticos da América S/A (DASA), Department of Molecular Diagnostics and Development, São Paulo, Brazil;3. Associate Professor of Gastroenterology and Hepatology, Federal University of Rio Grande do Sul, Porto Alegre, Brazil;4. Global Epidemiology and Outcome Research, Bristol-Myers Squibb, Wallingford, USA and Adjunct Assistant Professor, Yale University School of Medicine, New Haven CT, USA;5. Global Development and Medical Affairs, Bristol-Myers Squibb, Princeton, USA |
| |
Abstract: | Serum hepatitis B virus (HBV) DNA level is a predictor of the development of cirrhosis and hepatocellular carcinoma in chronic hepatitis B patients. Nevertheless, the distribution of viral load levels in chronic HBV patients in Brazil has yet to be described. This cross-sectional study included 564 participants selected in nine Brazilian cities located in four of the five regions of the country using the database of a medical diagnostics company. Admission criteria included hepatitis B surface antigen seropositivity, availability of HBV viral load samples and age ≥ 18 years. Males comprised 64.5% of the study population. Mean age was 43.7 years. Most individuals (62.1%) were seronegative for the hepatitis B e antigen (HBeAg). Median serum ALT level was 34 U/L. In 58.5% of the patients HBV-DNA levels ranged from 300 to 99,999 copies/mL; however, in 21.6% levels were undetectable. Median HBV-DNA level was 2,351 copies/mL. Over 60% of the patients who tested negative for HBeAg and in whom ALT level was less than 1.5 times the upper limit of the normal range had HBV-DNA levels > 2,000 IU/mL, which has been considered a cut-off point for indicating a liver biopsy and/or treatment. In conclusion, HBV-DNA level identified a significant proportion of Brazilian individuals with chronic hepatitis B at risk of disease progression. Furthermore, this tool enables those individuals with high HBV-DNA levels who are susceptible to disease progression to be identified among patients with normal or slightly elevated ALT. |
| |
Keywords: | |
本文献已被 ScienceDirect 等数据库收录! |
|